dual gip/glp-1 receptor agonist The Sustained Effects of a Agonist, NNC0090-2746, in Patients with Type 2 Diabetes glp 1 and gip glp
Description
288 (2), R384R388 (2005)
It attained FDA approval in 2016 for the management of T2D
The population in SELECT was different that STEP-1 and SUMOUNT 1, with 90.1% of patients on lipid-lowering therapy and a much lower baseline LDL-C of 78 mg/dL compared to 111 mg/dL and 110 mg/dL in STEP-1 and SURMOUNT 1 respectively [33, 35, 48]
In an animal study, using a mouse model with different age groups, non-alcoholic steatohepatitis (NASH) was induced, revealing age-dependent effects on cardiac function
